Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients - Wikidata - wikimedia - TriplyDB

Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

http://www.wikidata.org/entity/Q33621891

about

Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.Immune DNA signature of T-cell infiltration in breast tumor exomes.Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy Targeting CD137 enhances the efficacy of cetuximab.NK cells and T cells cooperate during the clinical course of colorectal cancer.Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.Natural killer cells in non-hematopoietic malignancies HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.NK cell-based autologous immune enhancement therapy (AIET) for cancer.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance.Combining immunotherapy and targeted therapies in cancer treatment.Combination strategies to enhance antitumor ADCC.NK cells: key to success of DC-based cancer vaccines?Perioperative propofol-paravertebral anesthesia decreases the metastasis and progression of breast cancer.Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy Radiolabelled polymeric IgA: from biodistribution to a new molecular imaging tool in colorectal cancer lung metastases.Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance.Evolving notions on immune response in colorectal cancer and their implications for biomarker development.

P2860

Q27329648-B5D8E5EF-236E-4109-9AB2-B3DA6B458F99 Q30377226-3F774B55-E337-4EF0-AE33-79F236068CF5 Q33736664-1DD3664F-3C02-4F82-8181-06E9A9794731 Q33872482-09A5068C-9320-454A-82A8-891EB80833A2 Q34933101-379BDB5A-81E9-417A-9213-6FEF91AA7FFC Q35933551-18D37C9B-2F41-49AA-9F6E-37A9A2C07B44 Q36486204-369255E0-81C7-4328-902E-EA7676AFD1D7 Q36544773-B4FC06A8-9D08-4F3A-81C7-1EFCF0E83DF7 Q37218978-F0B61441-DB14-4239-B567-FDE50E454EC9 Q37536206-A6F489E9-9580-4012-A8F9-213422720473 Q37616478-B54754CA-5914-4807-B854-98992659C6B7 Q37735615-7F3B9B02-1252-495E-9A72-C83D1F93B19B Q37945304-C97D0841-0764-43C9-BAD8-2983F5665B0E Q37995939-9C148E22-FB37-474A-A11E-B580DAAFBE84 Q38014085-881F5264-1A41-4E2A-8F13-777CB5EE3215 Q38036202-1AF03E2A-ACE4-4D44-AB0F-4173380F0603 Q38588910-F4B0A2EA-6BD5-4431-B5B0-5B318D2DF6F3 Q42505702-E85BD245-3392-42CD-834A-048BB844A57A Q47114808-25CD9A1D-60DE-4D92-BBC1-0C7C345FBD0B Q49295280-780BA48B-5466-419C-BFDA-D6471AFA8778 Q50098505-5A129148-4640-43CE-811B-88F9084B244F

P2860

Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

http://www.wikidata.org/entity/Q33621891

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Putative contribution of CD56 ...... tic colorectal cancer patients

@ast

Putative contribution of CD56 ...... tic colorectal cancer patients

@en

type

label

Putative contribution of CD56 ...... tic colorectal cancer patients

@ast

Putative contribution of CD56 ...... tic colorectal cancer patients

@en

prefLabel

Putative contribution of CD56 ...... tic colorectal cancer patients

@ast

Putative contribution of CD56 ...... tic colorectal cancer patients

@en

P1433

Q33621891-E038BAA5-5611-430B-BC80-8E99E8779792

P1476

Q33621891-810B8F3C-B7A8-40AD-A0B1-56A972BE060E

P2093

Q33621891-5DA5CF4C-0FDC-4B78-807E-282D1486D7DA

Q33621891-7007896B-9A6F-4407-AA1A-C9074EC3EAC8

Q33621891-982DA1A5-3470-46F5-A7A9-CAEAFA77F03C

Q33621891-E290E919-F660-41FC-9CD0-70B8E761DD57

Q33621891-E3F05743-2707-4D18-8EB4-B798DE7BD99B

Q33621891-F19075CC-36BC-492E-9F7A-F59EC4ABA3A0

P2860

Q33621891-0746FB2C-9AF5-4C58-8E57-88CE13E0006F

Q33621891-0ED7BDF2-93BD-441A-8FC3-D85BE4DFA957

Q33621891-17B47187-AD3F-4B52-B277-BC8B56779AA5

Q33621891-2672871C-3FBA-4B87-B717-C4CEF51495F3

Q33621891-285D5A4A-F499-42BB-9548-B5108F273EA4

Q33621891-2B1C6CB4-123D-4B2D-90C2-AA739C886FE7

Q33621891-31A3520B-C559-4312-ADBE-CBF2C3ED0B9C

Q33621891-38B87ABB-018B-4586-8D2B-086415204AE8

Q33621891-3E803DB6-DA52-4396-960A-D8D60A7C4A7D

Q33621891-3F3B8DB7-A1CD-46E6-A162-86152F2CD07D

P2888

Q33621891-16477EAB-06D7-4BF0-A5FC-165C892B4023

P304

Q33621891-6630788A-4DA2-46FB-902B-3AEC820107BF

P31

Q33621891-067DB76C-79BC-4FA1-878C-22B3E839E5DD

P356

Q33621891-650399EE-A7B0-4BB1-9878-C85E1697BBC8

P407

Q33621891-69CBB746-9567-45B9-B45C-BA7B03C6AEC9

P478

Q33621891-5295AC2B-9C69-481A-8132-449E20BC24AD

P50

Q33621891-18183900-917E-43F6-8784-6F293E27C78C

Q33621891-3E31EE31-045F-437E-BD93-F7AFC60C23D4

Q33621891-88CCC324-2BAF-4A0D-B703-246AEA0CC8FE

P577

Q33621891-4CBA9AF9-E400-4A01-BBCE-0C24FAE71005

P5875

Q33621891-A3C79A39-C3EE-483D-BACE-86740C5AFF71

P6179

Q33621891-87FBEF45-AD11-410C-BA8F-CDC90E4C97BA

P698

Q33621891-0DBA77E3-BDFA-4577-A70A-E5634DBB654B

P921

Q33621891-9A04C3D7-DD41-4C6F-84DD-1B0A54B24382

Q33621891-E225CA5A-B8A9-401B-B9CC-C00066ED36BE

P932

Q33621891-BF58EF76-F242-470C-B25B-06A655D71A8F

P356

1471-2407-10-340

P1433

P1476

Putative contribution of CD56 ...... tic colorectal cancer patients

@en

P2093

Arnaud Lemmers

http://www.w3.org/2001/XMLSchema#string

Isabelle Salmon

http://www.w3.org/2001/XMLSchema#string

Jacques Devière

http://www.w3.org/2001/XMLSchema#string

Nathalie Nagy

http://www.w3.org/2001/XMLSchema#string

Pieter Demetter

http://www.w3.org/2001/XMLSchema#string

Raphaël Maréchal

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells.

P2888

1471-2407-10-340

P304

340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-10-340

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Jef De Schutter

Jean-Luc Van Laethem

P577

2010-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44887897

http://www.w3.org/2001/XMLSchema#string

P6179

1027125445

http://www.w3.org/2001/XMLSchema#string

P698

20591136

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2912265

http://www.w3.org/2001/XMLSchema#string